Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies
The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmar...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
There are an array of new strategies evolving to manage relapsed chronic lymphocytic leukemia (CLL). In this interview, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospi...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Individualizing patient care in CML and MPNs
This is an exciting time for chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPNs), with new treatments on the horizon. Here, Claire Harrison, MD, FRCP, FRCPath, from Guy's and St Tho...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel Treatments for Acute Myeloid Leukemia Four New Drugs Approved
Amer M Zeidan, MBBS, discusses Novel Treatments for Acute Myeloid Leukemia Four New Drugs Approved at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Key Insights: Leukemia, Benign Hematology, & Myeloid Disorders
Co-chair Dr. David P. Steensma summarizes the key take-home points presented during the sessions on leukemia, benign hematology, and myeloid disorders at this years Great Debates & Updates in Hematol...
Author: imedex
Added: 04/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Tailoring Therapy to Older Patients with Acute Myeloid Leukemia
Presented by Aziz Nazha, MD. Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60% of newly diagnosed AML patients being 60 or older. Older patient...
Author: MediComOncology
Added: 03/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents
Presented by Ehab Atallah, MD. There is a significant unmet need in existing treatment paradigms for patients with acute myeloid leukemia (AML) due to poor survival and intolerability to cytotoxic che...
Author: MediComOncology
Added: 03/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Harnessing T-cells in acute leukemia and an anti-CD33/CD3 BiTE antibody
To date, stem cell transplantation has been the best curative treatment method for acute leukemia, for which T-cells are the faciliatators of the graft versus leukemia response. As explained here by M...
Author: VJHemOnc
Added: 03/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 12, 2018 Category: Cancer & Oncology Source Type: podcasts
T-cell engaging antibodies: novel combinations to overcome resistance
Acute leukemias can exhibit resistance to T-cell engaging antibodies through immune evasion, via both innate and adaptive mechanisms. In this interview, Marion Subklewe, MD, of LMU-University Hospital...
Author: VJHemOnc
Added: 03/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 12, 2018 Category: Cancer & Oncology Source Type: podcasts
Target antigens for T-cell engager therapies in ALL and AML
T-cell engaging antibodies are more straightforward to deisgn and use in acute lymphoblastic leukemia (ALL) compared with acute myeloid leukemia (AML), and have thus had more success. Here, Marion Sub...
Author: VJHemOnc
Added: 03/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 12, 2018 Category: Cancer & Oncology Source Type: podcasts
The diagnosis of early T-cell precursor (ETP) ALL
Our knowledge of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is advancing, as highlighted by an excellent talk on the topic at the 1st International Workshop on Acute Leukemias (iwAL...
Author: VJHemOnc
Added: 03/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Molecular subtypes of ALL: coming to a consensus
We are continually learning new facts about the molecular basis of acute lymphoblastic leukemia (ALL) and how it is evolving. In this insightful interview, Bijal Shah, MD, of the H. Lee Moffitt Cancer...
Author: VJHemOnc
Added: 03/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Status of the ZUMA-3 trial of CAR T-cell product KTE-C19 for R/R ALL
CAR T-cells for acute lymphoblastic leukemia (ALL) treatment are promising, with a number of different agents in development. Here, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research I...
Author: VJHemOnc
Added: 03/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
How should we utilizing molecular data to improve ALL treatment?
Certain molecular lesions are inherently targetable in acute lymphoblastic leukemia (ALL); patients with these changes should be given access to therapy that specifically targets these lesions. Speaki...
Author: VJHemOnc
Added: 03/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Future frontiers in AML: the five key therapy pillars & amp; the future of trials
Acute myeloid leukemia (AML) is experiencing a therapy boom, with increasing numbers of novel treatments being approved and more in the pipeline, for both frontline and salvage therapy. Here, Naval Da...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
